Medley Maintains Board Lineup and Sets 2026 Management Structure

Medley ( (JP:4480) ) just unveiled an update.

Medley has proposed reappointing its existing board, including President and CEO Kohei Takiguchi and CFO Ryo Kawahara, with all internal and independent external directors slated for re-nomination at the upcoming shareholders’ meeting in March 2026. The company also set its executive and management structure for the fiscal year ending December 2026, clarifying leadership roles across its HR and medical platform businesses, finance, legal and compliance, and corporate functions, signaling continuity in governance and a stable organizational framework as it executes its business strategy.

The new structure will see Takiguchi continue as representative director and CEO, with Ishizaki leading the HR Platform Business and Shishido and Yamazaki heading technology for the Medical Platform Business. Medley is reinforcing specialized roles such as CHRO, GC, VPoE, and CFO positions within both HR and medical platforms, which is likely aimed at strengthening operational oversight, technological development, and corporate governance to support long-term growth and stakeholder confidence.

The most recent analyst rating on (JP:4480) stock is a Hold with a Yen2772.00 price target. To see the full list of analyst forecasts on Medley stock, see the JP:4480 Stock Forecast page.

More about Medley

Medley, Inc. is a Japan-based company listed on the TSE Prime Market that operates platform businesses centered on the human resources and medical sectors. The company provides HR platform services and a medical platform business, supported by dedicated leadership teams overseeing finance, legal and compliance, corporate communications, and technology functions across these domains.

Average Trading Volume: 293,557

Technical Sentiment Signal: Sell

Current Market Cap: Yen78.17B

Learn more about 4480 stock on TipRanks’ Stock Analysis page.